GoodRx Holdings Future Growth
Future criteria checks 3/6
GoodRx Holdings is forecast to grow earnings and revenue by 40.4% and 7.6% per annum respectively. EPS is expected to grow by 42.6% per annum. Return on equity is forecast to be 14.4% in 3 years.
Key information
40.4%
Earnings growth rate
42.6%
EPS growth rate
Healthcare Services earnings growth | 27.4% |
Revenue growth rate | 7.6% |
Future return on equity | 14.4% |
Analyst coverage | Good |
Last updated | 12 Apr 2024 |
Recent future growth updates
Recent updates
GoodRx Holdings: Large TAM Continues To Support Growth
Mar 20GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mar 07Is GoodRx Holdings, Inc. (NASDAQ:GDRX) Trading At A 24% Discount?
Mar 01GoodRx Holdings (NASDAQ:GDRX) Has A Rock Solid Balance Sheet
Feb 12GoodRx: Cost Saving Is A Strong Value Proposition To Consumers
Jan 23GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Jan 22GoodRx Stock Spikes After Receiving A Strong Dose Of Performance
Jan 11What Is GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Share Price Doing?
Dec 02GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Sep 12An Intrinsic Calculation For GoodRx Holdings, Inc. (NASDAQ:GDRX) Suggests It's 41% Undervalued
Jul 14GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital Not Reflecting Well On The Business
May 27Some Confidence Is Lacking In GoodRx Holdings, Inc. (NASDAQ:GDRX) As Shares Slide 27%
May 05Investors Give GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares A 27% Hiding
May 05Is There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 45% Undervaluation?
Mar 23GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital
Feb 07GoodRx Holdings (NASDAQ:GDRX) Could Be Struggling To Allocate Capital
Nov 02GoodRx laying off 140 employees, 16% of workforce
Aug 31GoodRx: Trending Positive, But Not A Buy Yet
Aug 25GoodRx: Unexpected Short Squeeze As Grocer Issue Resolved
Aug 09GoodRx: Unexpected Wrench Pushes Me To The Sidelines
Jul 25Here's What's Concerning About GoodRx Holdings' (NASDAQ:GDRX) Returns On Capital
Jul 20GoodRx: Guidance Gets Worse, Stay Clear
May 19GoodRx: Time To Buy The Dip
Apr 23Returns On Capital Signal Tricky Times Ahead For GoodRx Holdings (NASDAQ:GDRX)
Apr 19GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Intrinsic Value Is Potentially 80% Above Its Share Price
Mar 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 936 | 126 | 269 | 289 | 11 |
12/31/2025 | 858 | 85 | 213 | 235 | 19 |
12/31/2024 | 801 | 48 | 179 | 223 | 18 |
12/31/2023 | 750 | -9 | 83 | 138 | N/A |
9/30/2023 | 738 | 15 | 96 | 154 | N/A |
6/30/2023 | 745 | 12 | 69 | 128 | N/A |
3/31/2023 | 747 | -48 | 92 | 149 | N/A |
12/31/2022 | 767 | -33 | 92 | 147 | N/A |
9/30/2022 | 796 | -71 | 116 | 165 | N/A |
6/30/2022 | 803 | -47 | 136 | 180 | N/A |
3/31/2022 | 788 | -15 | 126 | 163 | N/A |
12/31/2021 | 745 | -25 | 144 | 179 | N/A |
9/30/2021 | 686 | -282 | 109 | 144 | N/A |
6/30/2021 | 631 | -314 | 84 | 128 | N/A |
3/31/2021 | 578 | -310 | 89 | 131 | N/A |
12/31/2020 | 551 | -294 | 96 | 131 | N/A |
9/30/2020 | 510 | 13 | 105 | 133 | N/A |
6/30/2020 | 472 | 75 | 105 | 117 | N/A |
3/31/2020 | 435 | 50 | 96 | 104 | N/A |
12/31/2019 | 388 | 42 | 78 | 83 | N/A |
12/31/2018 | 250 | 14 | 42 | 45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GDRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: GDRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GDRX is expected to become profitable in the next 3 years.
Revenue vs Market: GDRX's revenue (7.6% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: GDRX's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GDRX's Return on Equity is forecast to be low in 3 years time (14.4%).